Term Territory Sample Clauses

Term Territory. 2.1 The Term shall commence on the date hereof and continue, unless extended or suspended as provided herein, for an initial Contract Period (sometimes referred to as the "Initial Period") and the Option Periods provided for below. The Initial Period shall continue until the later of (i) eighteen (18) months after Your Delivery of the last Record in fulfillment of Your Recording Commitment for such period, but in no event earlier than twelve (12) months after the date thereof or (ii) the date upon which Company enters into a Distribution Agreement.
Sample 1
AutoNDA by SimpleDocs
Term Territory. This Agreement shall become effective on the Effective Date and shall continue in full force and effect for a term of three (3) years after Commercial Service Launch Date (“Initial Term”), and shall automatically renew for successive terms of one (1) year each, unless terminated earlier as provided for herein (Initial Term and such successive one-year terms, as the case may be, shall be collectively referred to as the “Term”).
Sample 1
Term Territory. The initial term ('Initial Term') of this agreement is three (3) years, which shall commence as of the date of this agreement. Promoter/Producer shall have the option to extend the Initial Term for an additional three (3) years by giving Sanctioning Body its written election to extend by no later than 120 days prior to the expiration of the Initial Term. Promoter/Producer reserves the right to terminate this agreement after the first year but guarantees the presentation of the first year. The Event Territory covered by this Agreement is all states west of the Mississippi River. Provided, however, the licensing territory described in the separate license agreement attached hereto and incorporated herein by reference is North America.
Sample 1
Term Territory. The License granted hereunder shall commence on the date hereof and shall remain in full force and effect in perpetuity, and may be used by Assignee throughout the world.
Sample 1
Term Territory. 2.01. The term of this Content Integration Agreement (“Term”) will begin as of the Launch Date and will continue for a period ending on the date that is [CONFIDENTIAL PORTION
Sample 1
Term Territory. This Agreement shall commence upon the effective Date, as stated above, and will continue until . They referee has been allocated to fulfil the requirements of the Find It Locally Antiques Page for Melbourne with a total amount of 60 clients/customers.
Sample 1
Term Territory. The rights of the Content assigned to Songdew under this agreement (as per Clause 2 above )will be valid for the entire universe and will be valid for perpetuity from the date of commercial release of the same.
Sample 1
AutoNDA by SimpleDocs
Term Territory 
Sample 1Sample 2

Related to Term Territory

  • Licensed Territory Worldwide NIH Patent License Agreement—Exclusive APPENDIX C – ROYALTIES Royalties:

  • Territory 43.1 This Agreement applies to the territory in which Verizon operates as an Incumbent Local Exchange Carrier in the Commonwealth of Pennsylvania. Verizon shall be obligated to provide Services under this Agreement only within this territory.

  • Commercialization License Subject to the terms of this Agreement, including without limitation Section 2.2 and Theravance's Co-Promotion rights in Section 5.3.2, Theravance hereby grants to GSK, and GSK accepts, an exclusive license under the Theravance Patents and Theravance Know-How to make, have made, use, sell, offer for sale and import Alliance Products in the Territory.

  • Licensed Product “Licensed Product” shall mean any article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights. For clarity, a “Licensed Product” shall not include other product or material that (a) is used in combination with Licensed Product, and (b) does not constitute an article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Commercialization Activities Within North America, the Parties will use Commercially Reasonable Efforts to Commercialize Licensed Products in the Field. In addition, within North America and subject to Section 2.7.6, the Parties will use Commercially Reasonable Efforts to conduct the Commercialization activities assigned to them pursuant to the Commercialization Plan/Budget, including the performance of detailing in accordance therewith. In conducting the Commercialization activities, the Parties will comply with all Applicable Laws, applicable industry professional standards and compliance policies of Celgene which have been previously furnished to Acceleron, as the same may be updated from time to time and provided to Acceleron. Neither Party shall make any claims or statements with respect to the Licensed Products that are not strictly consistent with the product labeling and the sales and marketing materials approved for use pursuant to the Commercialization Plan/Budget.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Regulatory Approval 25.1 The Parties understand and agree that this Agreement and any amendment or modification hereto will be filed with the Commission for approval in accordance with Section 252 of the Act and may thereafter be filed with the FCC. The Parties believe in good faith and agree that the services to be provided under this Agreement are in the public interest. Each Party covenants and agrees to fully support approval of this Agreement by the Commission or the FCC under Section 252 of the Act without modification.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Competing Products The provisions of Section 21 are set forth on attached Exhibit H and are incorporated in this Section 21 by this reference.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!